share_log

T2 Biosystems | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)

T2 Biosystems | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)

T2 Biosystems | SC 13G/A:超过5%持股股东披露文件(修正)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)
美股SEC公告 ·  2024/08/15 19:27

Moomoo AI 已提取核心信息

On April 12, 2024, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing indicated that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a United States citizen, have reported beneficial ownership of T2 Biosystems' common stock. Both New Dimensions and Safier reported sole voting and dispositive power over 755,000 shares, representing 4.3% of the company's class of securities based on 17,479,954 shares outstanding as reported in T2 Biosystems' Quarterly Statement on Form 10-Q filed on August 8, 2024. The filing, made under Rule 13d-1(c), certifies that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The certification was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on August 15, 2024.
On April 12, 2024, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing indicated that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a United States citizen, have reported beneficial ownership of T2 Biosystems' common stock. Both New Dimensions and Safier reported sole voting and dispositive power over 755,000 shares, representing 4.3% of the company's class of securities based on 17,479,954 shares outstanding as reported in T2 Biosystems' Quarterly Statement on Form 10-Q filed on August 8, 2024. The filing, made under Rule 13d-1(c), certifies that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The certification was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on August 15, 2024.
2024年4月12日,医疗器械公司t2 biosystems被美国证券交易委员会的13G日程备案所涉及。备案显示,位于开曼群岛的新尺度交易有限公司和美国公民杰各布·萨菲尔报告其对t2 biosystems普通股的实际所有权。新尺度和萨菲尔均报告单独持有755,000股的投票和处理权,占t2 biosystems类证券的4.3%,基于t2 biosystems于2024年8月8日提交的10-Q季度报告中的17,479,954股流通股。根据13d-1(c)规则提交备案,证明这些股份并非为改变或影响发行人的控制目的而收购,也不是与具有这种目的或影响的任何交易有关。备案由新尺度交易有限公司的董事Chana Edelstein和Jacob Safier于2024年8月15日签署。
2024年4月12日,医疗器械公司t2 biosystems被美国证券交易委员会的13G日程备案所涉及。备案显示,位于开曼群岛的新尺度交易有限公司和美国公民杰各布·萨菲尔报告其对t2 biosystems普通股的实际所有权。新尺度和萨菲尔均报告单独持有755,000股的投票和处理权,占t2 biosystems类证券的4.3%,基于t2 biosystems于2024年8月8日提交的10-Q季度报告中的17,479,954股流通股。根据13d-1(c)规则提交备案,证明这些股份并非为改变或影响发行人的控制目的而收购,也不是与具有这种目的或影响的任何交易有关。备案由新尺度交易有限公司的董事Chana Edelstein和Jacob Safier于2024年8月15日签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息